UA117182C2 - Нові композиції, їх використання і способи одержання - Google Patents

Нові композиції, їх використання і способи одержання

Info

Publication number
UA117182C2
UA117182C2 UAA201612474A UAA201612474A UA117182C2 UA 117182 C2 UA117182 C2 UA 117182C2 UA A201612474 A UAA201612474 A UA A201612474A UA A201612474 A UAA201612474 A UA A201612474A UA 117182 C2 UA117182 C2 UA 117182C2
Authority
UA
Ukraine
Prior art keywords
methods
making
novel compositions
present
compounds
Prior art date
Application number
UAA201612474A
Other languages
English (en)
Inventor
Мустафа ХАДДАХ
Original Assignee
Паймера, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54393079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117182(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Паймера, Інк. filed Critical Паймера, Інк.
Publication of UA117182C2 publication Critical patent/UA117182C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Загалом, даний винахід надає нові сполуки хінолонів і їх фармацевтичну композицію, які можуть інгібувати клітинну проліферацію і/або індукувати апоптоз клітин. Даний винахід також стосується способів одержання таких сполук і композицій, а також способів їх створення і використання.
UAA201612474A 2014-05-09 2015-05-09 Нові композиції, їх використання і способи одержання UA117182C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991282P 2014-05-09 2014-05-09
US201462050202P 2014-09-15 2014-09-15
US201462054054P 2014-09-23 2014-09-23
US201562128208P 2015-03-04 2015-03-04
PCT/US2015/030046 WO2015172123A1 (en) 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them

Publications (1)

Publication Number Publication Date
UA117182C2 true UA117182C2 (uk) 2018-06-25

Family

ID=54393079

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201612474A UA117182C2 (uk) 2014-05-09 2015-05-09 Нові композиції, їх використання і способи одержання

Country Status (33)

Country Link
US (1) US9512123B2 (uk)
EP (2) EP3140305B1 (uk)
JP (2) JP6188179B2 (uk)
KR (3) KR101890505B1 (uk)
CN (2) CN106995443B (uk)
AU (3) AU2015255738C1 (uk)
BR (1) BR112016026150B1 (uk)
CA (2) CA2974960A1 (uk)
CL (2) CL2016002798A1 (uk)
CY (1) CY1120935T1 (uk)
DK (1) DK3140305T3 (uk)
EA (1) EA034235B1 (uk)
EC (3) ECSP16088687A (uk)
ES (1) ES2679628T3 (uk)
HR (1) HRP20181105T1 (uk)
HU (1) HUE039733T2 (uk)
IL (2) IL248638B (uk)
LT (1) LT3140305T (uk)
MX (1) MX388752B (uk)
NI (1) NI201600168A (uk)
NZ (1) NZ725917A (uk)
PE (2) PE20170678A1 (uk)
PH (2) PH12016502213B1 (uk)
PL (1) PL3140305T3 (uk)
PT (1) PT3140305T (uk)
RS (1) RS57493B1 (uk)
SG (2) SG10201703658SA (uk)
SI (1) SI3140305T1 (uk)
SM (1) SMT201800418T1 (uk)
TR (1) TR201809990T4 (uk)
UA (1) UA117182C2 (uk)
WO (1) WO2015172123A1 (uk)
ZA (1) ZA201607573B (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
EP3601286A4 (en) * 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
CN112300173B (zh) * 2019-07-30 2021-10-01 上海凌达生物医药有限公司 一类含氮多环类化合物、制备方法和用途
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN110606850A (zh) * 2019-09-11 2019-12-24 中山大学 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2022135590A1 (zh) * 2020-12-27 2022-06-30 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113416197B (zh) * 2021-08-25 2021-12-28 北京鑫开元医药科技有限公司 甲酰胺类衍生物、制备方法、药物组合物及应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) * 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
WO1994000451A1 (de) * 1992-06-22 1994-01-06 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO[4',5' : 3,4]PYRROLO-[2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN
DE19509043A1 (de) * 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
CA2424303A1 (en) 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
BRPI0409105A (pt) 2003-04-07 2006-04-25 Cylene Pharmaceuticals Inc análogos de quinobenzoxazina substituìdos
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
WO2006034113A2 (en) 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
ITMI20042476A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Derivati indolici ad attivita' antitumorale
US7402579B2 (en) 2005-04-15 2008-07-22 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and compositions
US7816524B2 (en) 2005-08-05 2010-10-19 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
CA2621261C (en) * 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EP2023720A4 (en) * 2006-05-17 2009-06-10 Cylene Pharmaceuticals Inc TETRACYCLIC IMIDAZOLE ANALOG
DE102006051796A1 (de) 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
WO2008156879A1 (en) 2007-06-20 2008-12-24 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
JP5801193B2 (ja) 2008-11-03 2015-10-28 エルジー・ケム・リミテッド 新しい含窒素複素環化合物およびそれを用いた有機電子素子
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
KR101561730B1 (ko) * 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자

Also Published As

Publication number Publication date
CN106995443B (zh) 2022-01-11
WO2015172123A1 (en) 2015-11-12
PL3140305T3 (pl) 2018-10-31
SI3140305T1 (sl) 2018-09-28
KR101890505B1 (ko) 2018-09-28
HRP20181105T1 (hr) 2018-09-21
RS57493B1 (sr) 2018-10-31
AU2017203955A1 (en) 2017-07-06
CY1120935T1 (el) 2019-12-11
EA034235B1 (ru) 2020-01-20
IL264454A (en) 2019-02-28
KR20170042821A (ko) 2017-04-19
SMT201800418T1 (it) 2018-09-13
EP3140305A4 (en) 2017-03-15
PE20170131A1 (es) 2017-03-19
PH12016502213B1 (en) 2018-09-12
SG10201703658SA (en) 2017-06-29
TR201809990T4 (en) 2018-08-27
AU2015255738B2 (en) 2017-04-27
SG11201609171XA (en) 2016-12-29
US20160326176A1 (en) 2016-11-10
NZ725917A (en) 2017-07-28
BR112016026150B1 (pt) 2019-11-05
JP2017514889A (ja) 2017-06-08
CA2948173C (en) 2018-06-19
PH12016502213A1 (en) 2017-01-16
CN106459068A (zh) 2017-02-22
KR20180118806A (ko) 2018-10-31
DK3140305T3 (en) 2018-07-30
JP2017101038A (ja) 2017-06-08
MX388752B (es) 2025-03-20
JP6188179B2 (ja) 2017-08-30
ECSP16088687A (es) 2017-01-31
IL248638B (en) 2019-02-28
HUE039733T2 (hu) 2019-01-28
LT3140305T (lt) 2018-09-10
KR102044648B1 (ko) 2019-11-13
EP3219716B1 (en) 2024-12-25
EA201692269A1 (ru) 2017-04-28
ZA201607573B (en) 2018-08-30
CL2016002798A1 (es) 2017-03-10
EP3219716A1 (en) 2017-09-20
AU2017202145A1 (en) 2017-04-20
ES2679628T3 (es) 2018-08-29
CA2974960A1 (en) 2015-11-12
EP3140305B1 (en) 2018-04-18
PT3140305T (pt) 2018-07-24
ECSP17031525A (es) 2017-06-30
CL2017000372A1 (es) 2017-09-08
AU2015255738A1 (en) 2016-11-24
ECSP18049420A (es) 2018-07-31
AU2015255738C1 (en) 2017-09-28
KR20160144509A (ko) 2016-12-16
PH12017500660A1 (en) 2019-03-04
CA2948173A1 (en) 2015-11-12
AU2017202145B2 (en) 2019-02-21
CN106459068B (zh) 2019-01-22
PE20170678A1 (es) 2017-06-03
NI201600168A (es) 2017-01-26
EP3140305A1 (en) 2017-03-15
CN106995443A (zh) 2017-08-01
US9512123B2 (en) 2016-12-06
MX2016014555A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
PH12017500660A1 (en) Novel compositions, uses and methods for making them
PH12018500907A1 (en) Inhibitors of ret
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
WO2015120062A8 (en) Therapeutic compounds and compositions
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12016501613B1 (en) Pyrazines modulators of gpr6
IN2014CH00840A (uk)
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
NZ721832A (en) Solid forms of tenofovir
IN2014MU00197A (uk)
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016015468A (es) Composiciones farmaceuticas que contienen montelukast y levocetirizina.
IN2014MU00815A (uk)
IN2014MU00814A (uk)